QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
BATS:HELX

Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free HELX Stock Alerts
$29.32
-0.33 (-1.11%)
(As of 04/19/2024 ET)
Compare
Today's Range
$29.32
▼
$29.36
50-Day Range
$29.90
▼
$32.92
52-Week Range
N/A
Volume
781 shs
Average Volume
N/A
Market Capitalization
$10.26 million
Assets Under Management
$8.91 million
Dividend Yield
N/A
Net Expense Ratio
0.50%
Stock AnalysisChartHoldingsOwnershipRatings

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.

HELX Stock Price History

HELX ETF News Headlines

March 27, 2024 | money.usnews.com
Franklin U.S. Treasury Bond ETF
November 25, 2023 | lse.co.uk
Franklin Msci China Paris Alig Ucits Etf Share Price (FRCP.MI)
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
November 17, 2023 | lse.co.uk
Franklin Emerging Markets Ucits Etf Share Price (FLXE.MI)
February 25, 2023 | morningstar.com
BMO ARK Genomic Revolution ETF Series
See More Headlines
Receive HELX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Franklin Templeton Investments
Fund Name
Franklin Genomic Advancements ETF
Tax Classification
Regulated Investment Company
Stock Exchange
BATS
Current Symbol
BATS:HELX
Inception Date
2/25/2020
Fund Manager
Matthew J.Moberg, Joyce Lin
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
65

Fund Statistics

Assets Under Management
$8.91 million
Average Daily Volume
$0.00
Discount/Premium
-0.03%

Administrator, Advisor and Custodian

Administrator
Franklin Templeton Services, LLC
Advisor
Franklin Advisers, Inc.
Custodian
State Street Bank and Trust Company
Distributor
Franklin Templeton Distributors, Inc.
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Citadel

Miscellaneous

Outstanding Shares
350,000
Beta
1.02
Creation Unit
50,000
Creation Fee
$200.00
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Ad Behind the Markets
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>

Franklin Genomic Advancements ETF Expenses

TypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFs
Management Fee0.50%0.57%0.54%0.56%0.51%
Other Expenses0.00%0.72%0.54%0.51%0.58%
Total Expense0.50%0.72%0.70%0.68%0.70%
Fee Waiver0.00%-0.76%-0.55%-0.34%-0.57%
Net Expense0.50%0.59%0.60%0.63%0.58%

Franklin Genomic Advancements ETF (HELX) Holdings & Exposure

Top 10 HELX Holdings

HELX Sector Exposure

HELX Industry Exposure

Full Holdings Details

HELX ETF - Frequently Asked Questions

How have HELX shares performed in 2024?

Franklin Genomic Advancements ETF's stock was trading at $30.47 at the beginning of 2024. Since then, HELX stock has decreased by 3.8% and is now trading at $29.3241.
View the best growth stocks for 2024 here.

What does HELX invest in?

Franklin Genomic Advancements ETF is a equity fund issued by Franklin Templeton Investments. HELX focuses on theme investments. The fund's investments total to approximately $8.91 million assets under management.

What stocks does Franklin Genomic Advancements ETF hold?

HELX invests in 65 holdings. Some of the stocks in their portfolio include Thermo Fisher Scientific (TMO), Danaher (DHR), Repligen (RGEN), Medpace (MEDP), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Krystal Biotech (KRYS), Corteva (CTVA), AstraZeneca (AZN) and Bruker (BRKR).

What is the management fee for Franklin Genomic Advancements ETF?

Franklin Genomic Advancements ETF's management fee is 0.50% and has no other recorded expenses or fee waivers. The net expense ratio for HELX is 0.50%.

How do I buy shares of Franklin Genomic Advancements ETF?

Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (BATS:HELX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media